NYSE:MRKPharmaceuticals
Merck (MRK) And Daiichi Sankyo's R-DXd Receives FDA Breakthrough Therapy Designation
Merck (MRK) experienced a 6% rise in its share price over the last quarter, coinciding with significant developments such as the FDA granting Breakthrough Therapy Designation for raludotatug deruxtecan—a potential first-in-class cancer treatment. Despite these positive advancements, the company's price movement aligns with broader market trends marked by record highs in Nasdaq and S&P 500 indices amid anticipated interest rate cuts. Alongside corporate earnings pressure and sales guidance...